{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T08:53:37Z","timestamp":1790499217397,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd012714","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T00:00:00Z","timestamp":1621900800000}}],"reference-count":50,"publisher":"Wiley","issue":"5","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd012714.pub2","type":"journal-article","created":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T08:32:40Z","timestamp":1621931560000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Medications for daytime sleepiness in individuals with idiopathic hypersomnia"],"prefix":"10.1002","volume":"2021","author":[{"given":"Lynn M","family":"Trotti","sequence":"additional","affiliation":[{"name":"Department of Neurology; Emory University School of Medicine; Atlanta USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorne A","family":"Becker","sequence":"additional","affiliation":[{"name":"Department of Family Medicine; SUNY Upstate Medical University; Syracuse New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Friederich Murray","sequence":"additional","affiliation":[{"name":"Prior founding board member; Hypersomnia Foundation; Scottsdale Arizona USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romy","family":"Hoque","sequence":"additional","affiliation":[{"name":"Department of Neurology; Emory University School of Medicine; Atlanta USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,5,25]]},"reference":[{"key":"10.1002\/14651858.CD012714.pub2-BIB0001|cit1","unstructured":"Inoue Y Tabata T Tsukimori N Efficacy and safety of modafinil in patients with idiopathic hypersomnia without long sleep time: a multicenter, randomized, double-blind, placebo-controlled, parallel-group comparison study Sleep Medicine 10.1016\/j.sleep.2021.01.018"},{"issue":"1","key":"10.1002\/14651858.CD012714.pub2-BIB0002|cit2","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1111\/jsr.12201","article-title":"Modafinil in the treatment of idiopathic hypersomnia without long sleep time-a randomized, double-blind, placebo-controlled study","volume":"24","author":"Mayer","year":"2015","journal-title":"Journal of Sleep Research"},{"issue":"3","key":"10.1002\/14651858.CD012714.pub2-BIB0003|cit3","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1002\/ana.24459","article-title":"Clarithromycin in gamma-aminobutyric acid-related hypersomnia: a randomized, crossover trial","volume":"78","author":"Trotti","year":"2015","journal-title":"Annals of Neurology"},{"key":"10.1002\/14651858.CD012714.pub2-BIB0004|cit4","unstructured":"Long-term study of CN-801 in patients with idiopathic hypersomnia www.clinicaltrials.jp\/user\/showCteDetailE.jsp?japicId=JapicCTI-142615"},{"key":"10.1002\/14651858.CD012714.pub2-BIB0005|cit5","unstructured":"Flumazenil for the treatment of primary hypersomnia clinicaltrials.gov\/show\/NCT01183312"},{"key":"10.1002\/14651858.CD012714.pub2-BIB0006|cit6","first-page":"771","article-title":"Preliminary trial of a new stimulant SCH 5472 in ambulatory patients with depression, exhaustion, or hypersomnia syndrome","volume":"7","author":"Nodine","year":"1960","journal-title":"Antibiotic Medicine & Clinical Therapy"},{"issue":"3","key":"10.1002\/14651858.CD012714.pub2-BIB0007|cit7","doi-asserted-by":"publisher","first-page":"483","DOI":"10.5665\/sleep.3480","article-title":"Modafinil improves real driving performance in patients with hypersomnia: a randomized double-blind placebo-controlled crossover clinical trial","volume":"37","author":"Philip","year":"2014","journal-title":"Sleep"},{"key":"10.1002\/14651858.CD012714.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.sleep.2018.02.009","article-title":"Maintenance of wakefulness test, real and simulated driving in patients with narcolepsy\/hypersomnia","volume":"55","author":"Sagaspe","year":"2019","journal-title":"Sleep Medicine"},{"key":"10.1002\/14651858.CD012714.pub2-BIB0009|cit9","unstructured":"A phase IIa study of GR3027 in patients with idiopathic hypersomnia (IH) involving an open-label part to assess safety, tolerability and pharmacokinetics (PK) of a single oral GR3027 dose in female patients and a randomized, double-blind, placebo-controlled crossover study to assess safety, tolerability, exposure and exploratory efficacy of multiple oral doses of GR3027 in male and female IH patients www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2017-002127-16"},{"key":"10.1002\/14651858.CD012714.pub2-BIB0010|cit10","unstructured":"A study of safety and efficacy of BTD-001 in treatment of patients with idiopathic hypersomnia (IH) or narcolepsy type 2 clinicaltrials.gov\/show\/NCT02512588"},{"key":"10.1002\/14651858.CD012714.pub2-BIB0011|cit11","unstructured":"A multicenter study of the efficacy and safety of JZP-258 in the treatment of idiopathic hypersomnia (IH) with an open-label safety extension clinicaltrials.gov\/show\/NCT03533114"},{"key":"10.1002\/14651858.CD012714.pub2-BIB0012|cit12","unstructured":"A randomized, placebo-controlled, double-blind, crossover study of oral BTD-001 in adults with idiopathic hypersomnia clinicaltrials.gov\/show\/NCT03542851"},{"key":"10.1002\/14651858.CD012714.pub2-BIB0013|cit13","unstructured":"Sodium oxybate for idiopathic hypersomnia clinicaltrials.gov\/show\/NCT03597555"},{"key":"10.1002\/14651858.CD012714.pub2-BIB0014|cit14","unstructured":"Modafinil versus amphetamines for the treatment of narcolepsy type 2 and idiopathic hypersomnia clinicaltrials.gov\/ct2\/show\/NCT03772314"},{"key":"10.1002\/14651858.CD012714.pub2-BIB0015|cit15","unstructured":"Clarithromycin mechanisms in hypersomnia syndromes clinicaltrials.gov\/ct2\/show\/NCT04026958"},{"key":"10.1002\/14651858.CD012714.pub2-BIB0016|cit16","unstructured":"A phase 1b randomized, double-blind, placebo-controlled, crossover study of a single intravenous infusion dose of TAK-925 in patients With idiopathic hypersomnia clinicaltrials.gov\/ct2\/show\/NCT04091438"},{"issue":"6","key":"10.1002\/14651858.CD012714.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"562","DOI":"10.5664\/jcsm.27658","article-title":"Idiopathic hypersomnia: clinical features and response to treatment","volume":"5","author":"Ali","year":"2009","journal-title":"Journal of Clinical Sleep Medicine"},{"issue":"10","key":"10.1002\/14651858.CD012714.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1093\/sleep\/30.10.1274","article-title":"Idiopathic hypersomnia: a study of 77 cases","volume":"30","author":"Anderson","year":"2007","journal-title":"Sleep"},{"issue":"5","key":"10.1002\/14651858.CD012714.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"339-54","DOI":"10.1016\/j.smrv.2004.03.002","article-title":"Pharmacotherapy for excessive daytime sleepiness","volume":"8","author":"Banerjee","year":"2004","journal-title":"Sleep Medicine Review"},{"key":"10.1002\/14651858.CD012714.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1093\/brain\/120.8.1423","article-title":"Idiopathic hypersomnia: a series of 42 patients","volume":"120","author":"Bassetti","year":"1997","journal-title":"Brain"},{"key":"10.1002\/14651858.CD012714.pub2-BIB0021|cit21","unstructured":"www.covidence.org"},{"key":"10.1002\/14651858.CD012714.pub2-BIB0022|cit22","unstructured":"European Medicines Agency Modafinil ww.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/referrals\/Modafinil\/human_referral_000236.jsp"},{"key":"10.1002\/14651858.CD012714.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1017\/S1092852914000583","article-title":"Mechanism of action of narcolepsy medications","volume":"19","author":"Gowda","year":"2014","journal-title":"CNS Spectrums"},{"key":"10.1002\/14651858.CD012714.pub2-BIB0024|cit24","unstructured":"McMaster University (developed by Evidence Prime) GRADEPro GDT"},{"key":"10.1002\/14651858.CD012714.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.neuropharm.2014.06.012","article-title":"Dopamine reuptake transporter (DAT) \u201cinverse agonism\u201d-a novel hypothesis to explain the enigmatic pharmacology of cocaine","volume":"87","author":"Heal","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1002\/14651858.CD012714.pub2-BIB0026|cit26","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]","year":"2011"},{"key":"10.1002\/14651858.CD012714.pub2-BIB0027|cit27","unstructured":"Higgins JP Thomas J Chandler J Cumpston M Li T Page MJ Welch VA Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021 Available from training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD012714.pub2-BIB0028|cit28","volume-title":"International Classification of Sleep Disorders, 3rd edition","author":"Sateia","year":"2014"},{"issue":"3","key":"10.1002\/14651858.CD012714.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"335","DOI":"10.5664\/jcsm.4554","article-title":"Quality measures for the care of patients with narcolepsy","volume":"11","author":"Krahn","year":"2015","journal-title":"Journal of Clinical Sleep Medicine"},{"key":"10.1002\/14651858.CD012714.pub2-BIB0030|cit30","unstructured":"Lefebvre C Glanville J Briscoe S Littlewood A Marshall C Technical Supplement to Chapter 4: Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021 Available from training.cochrane.org\/handbook"},{"issue":"6","key":"10.1002\/14651858.CD012714.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.sleep.2014.01.021","article-title":"Effects of pitolisant, a histamine H3 inverse agonist, in drug-resistant idiopathic and symptomatic hypersomnia: a chart review","volume":"15","author":"Leu-Semenescu","year":"2014","journal-title":"Sleep Medicine"},{"key":"10.1002\/14651858.CD012714.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.sleep.2015.10.005","article-title":"Benefits and risk of sodium oxybate in idiopathic hypersomnia versus narcolepsy type 1: a chart review","volume":"17","author":"Leu-Semenescu","year":"2016","journal-title":"Sleep Medicine"},{"issue":"2","key":"10.1002\/14651858.CD012714.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.5664\/jcsm.26527","article-title":"Sleep circuitry and the hypnotic mechanism of GABAA drugs","volume":"2","author":"Lu","year":"2006","journal-title":"Journal of Clinical Sleep Medicine"},{"key":"10.1002\/14651858.CD012714.pub2-BIB0034|cit34","doi-asserted-by":"publisher","DOI":"10.5664\/jcsm.9328","article-title":"Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine clinical practice guideline","author":"Maski","journal-title":"Journal of Clinical Sleep Medicine"},{"key":"10.1002\/14651858.CD012714.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1053\/smrv.2001.0216","article-title":"Idiopathic hypersomnia: a diagnostic dilemma. A commentary of \"Idiopathic hypersomnia\" (M. Billiard and Y. Dauvilliers)","volume":"5","author":"Montplaisir","year":"2001","journal-title":"Sleep Medicine Reviews"},{"issue":"12","key":"10.1002\/14651858.CD012714.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1093\/sleep\/30.12.1705","article-title":"Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin","volume":"30","author":"Morgenthaler","year":"2007","journal-title":"Sleep"},{"issue":"1","key":"10.1002\/14651858.CD012714.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.sleep.2012.07.008","article-title":"Mazindol in narcolepsy and idiopathic and symptomatic hypersomnia refractory to stimulants: a long-term chart review","volume":"14","author":"Nittur","year":"2013","journal-title":"Sleep Medicine"},{"issue":"6","key":"10.1002\/14651858.CD012714.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1002\/ana.23818","article-title":"Excessive sleep duration and quality of life","volume":"73","author":"Ohayon","year":"2013","journal-title":"Annals of Neurology"},{"issue":"2","key":"10.1002\/14651858.CD012714.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.sleep.2011.07.014","article-title":"Quality of life in patients with narcolepsy with cataplexy, narcolepsy without cataplexy, and idiopathic hypersomnia without long sleep time: comparison between patients on psychostimulants, drug-na\u00efve patients and the general Japanese population","volume":"13","author":"Ozaki","year":"2012","journal-title":"Sleep Medicine"},{"issue":"2","key":"10.1002\/14651858.CD012714.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1365-2869.2012.01061.x","article-title":"Polysomnographic study of nocturnal sleep in idiopathic hypersomnia without long sleep time","volume":"22","author":"Pizza","year":"2013","journal-title":"Journal of Sleep Research"},{"key":"10.1002\/14651858.CD012714.pub2-BIB0041|cit41","unstructured":"The Cochrane Collaboration Review Manager Web (RevMan Web) 2021"},{"issue":"161","key":"10.1002\/14651858.CD012714.pub2-BIB0042|cit42","doi-asserted-by":"publisher","first-page":"161ra151","DOI":"10.1126\/scitranslmed.3004685","article-title":"Modulation of vigilance in the primary hypersomnias by endogenous enhancement of GABAA receptors","volume":"4","author":"Rye","year":"2012","journal-title":"Science Translational Medicine"},{"key":"10.1002\/14651858.CD012714.pub2-BIB0043|cit43","unstructured":"Sch\u00fcnemann HJ Vist GE Higgins JPT Santesso N Deeks JJ Glasziou P Chapter 15: Interpreting results and drawing conclusions. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021 Available from training.cochrane.org\/handbook"},{"issue":"6","key":"10.1002\/14651858.CD012714.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.sleep.2011.02.004","article-title":"Effect of levothyroxine on prolonged nocturnal sleep time and excessive daytime somnolence in patients with idiopathic hypersomnia","volume":"12","author":"Shinno","year":"2011","journal-title":"Sleep Medicine"},{"issue":"2","key":"10.1002\/14651858.CD012714.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.sleep.2014.09.016","article-title":"Narcolepsy with and without cataplexy, idiopathic hypersomnia with and without long sleep time: a cluster analysis","volume":"16","author":"\u0160onka","year":"2015","journal-title":"Sleep Medicine"},{"issue":"7","key":"10.1002\/14651858.CD012714.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1177\/0269881113515062","article-title":"Improvement in daytime sleepiness with clarithromycin in patients with GABA-related hypersomnia: clinical experience","volume":"28","author":"Trotti","year":"2013","journal-title":"Journal of Psychopharmacology"},{"issue":"10","key":"10.1002\/14651858.CD012714.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.5664\/jcsm.6196","article-title":"Flumazenil for the treatment of refractory hypersomnolence: clinical experience with 153 patients","volume":"12","author":"Trotti","year":"2016","journal-title":"Journal of Clinical Sleep Medicine"},{"issue":"6","key":"10.1002\/14651858.CD012714.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1093\/sleep\/32.6.753","article-title":"Idiopathic hypersomnia with and without long sleep time: a controlled series of 75 patients","volume":"32","author":"Vernet","year":"2009","journal-title":"Sleep"},{"issue":"4","key":"10.1002\/14651858.CD012714.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/j.1365-2869.2010.00824.x","article-title":"Subjective symptoms in idiopathic hypersomnia: beyond excessive sleepiness","volume":"19","author":"Vernet","year":"2010","journal-title":"Journal of Sleep Research"},{"issue":"7","key":"10.1002\/14651858.CD012714.pub2-BIB0050|cit50","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012714","article-title":"Medications for daytime sleepiness in individuals with idiopathic hypersomnia","author":"Trotti","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2022,4,23]],"date-time":"2022-04-23T20:02:06Z","timestamp":1650744126000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD012714.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Epilepsy Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,5,25]]},"references-count":50,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,5]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd012714.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,25]]}}}